US2004137571A1PendingUtilityA1
Method for purifying a fermentation-derived product
Priority: Nov 26, 2002Filed: Nov 21, 2003Published: Jul 15, 2004
Est. expiryNov 26, 2022(expired)· nominal 20-yr term from priority
C07K 14/62C07K 1/30
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Process for purifying a fermentation-derived product.
Claims
exact text as granted — not AI-modified1 . A process for purifying a cell-derived product from a cell culture, said process comprising treating an extract of the cell culture or a growth medium of the culture at a temperature between about 60° C. to 90° C. and cooling the treated extract or growth medium to a temperature below about 60° C.
2 . A process according to claim 1 , further comprising subjecting the treated extract or growth medium to a separation step that separates the extract or growth medium into a precipitate and a soluble portion.
3 . A process according to claim 1 , wherein the treatment at a temperature between about 60° C. to 90° C. is for a period of time between about 1 min and about 60 min.
4 . A process according to claim 3 , wherein said time period of between about 1 min and about 30 min.
5 . A process according to claim 4 , wherein said time period is not more than about 10 min.
6 . A process according to claim 1 , wherein the extract or growth medium is cooled to a temperature below about 35° C.
7 . A process according to claim 1 , wherein the cell culture is selected from the group consisting of bacterial and yeast cells.
8 . A process according to claim 8 , wherein the cell culture is selected from the group consisting of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Pichia methanolica, Candida utilis and Kluyveromyces lactis.
9 . A process according to claim 1 , wherein the cell culture comprises recombinant cells.
10 . A process according to claim 1 , wherein the cell-derived product is a protein.
11 . A process according to claim 10 , wherein the protein has a molecular weight below about 25,000 daltons.
12 . A process for purifying a fermentation-derived product, said process comprising the steps of:
a) heating the fermentation broth containing said fermentation-derived product or a precursor thereof to a temperature in the range from 60° C. to 90° C., b) cooling the fermentation broth to a temperature below 60° C.; c) separating the precipitate from the soluble portion of the fermentation broth at a temperature less than 60° C.; and d) isolating said fermentation-derived product.
13 . The process according to claim 12 , wherein no flocculation agent is added to said fermentation broth.
14 . The process according to claim 12 , wherein the temperature of the fermentation broth during the separation step c) is less than about 40° C.
15 . The process according to claim 12 , wherein separation in step c) is performed by a method selected from the group consisting of centrifugation, microfiltration, and combinations of any of the foregoing.
16 . The process according to claim 12 , wherein the process steps a), b) and c) are run in continuous mode.
17 . The process according to claim 12 , wherein said soluble portion of the fermentation broth produced in step c) is subjected to a method selected from the group consisting of column chromatography; crystallization; precipitation; ultrafiltration; or combinations of any of the foregoing.
18 . The process according to claim 12 , wherein the cut-off value of the UF membrane is lower than about four times the molecular weight of the fermentation-derived product.
19 . The process according to claim 12 , wherein said fermentation-derived product or a precursor thereof is a protein.
20 . The process according to claim 19 , wherein said protein is selected from the group consisting of GLP-1, exendin-4, exendin-3, GLP-2, glucagon, TFF peptides, interleukins, insulin, albumin, precursors of any of the foregoing, and analogs of any of the foregoing.
21 . The process according to claim 20 , wherein said protein is selected from the group consisting of human insulin, a human insulin precursor, a human insulin analog, a human insulin analog precursor, Arg 34 -GLP-1 (7-37), and GluGluAlaGluLys-Arg 34 -GLP-1(7-37).Join the waitlist — get patent alerts
Track US2004137571A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.